Swiss pharmaceutical giant Roche (SWX: ROG) has reported an update on the phase III SKYSCRAPER-01 study, which evaluated the combination of tiragolumab with Tecentriq (atezolizumab) compared to Tecentriq alone for patients with PD-L1-high, locally advanced or metastatic non-small cell lung cancer (NSCLC).
SKYSCRAPER-01 Study Details and Results
The global, randomized, double-blind Phase III SKYSCRAPER-01 study included 534 patients with PD-L1-high, locally advanced or metastatic NSCLC. The study assessed the efficacy of tiragolumab combined with Tecentriq (atezolizumab) versus Tecentriq alone. Unfortunately, the primary endpoint of overall survival at the final analysis was not met. Despite this, the overall safety profile observed remained consistent with longer follow-up, with no new safety signals identified, indicating that the combination was not associated with unexpected adverse effects.
Previous SKYSCRAPER-06 Study Outcomes
Previously, the combination of tiragolumab and Tecentriq had also failed to meet the primary endpoints in the Phase II/III SKYSCRAPER-06 study, further highlighting the challenges in treating this patient population.
Ongoing Commitment to Research and Adjustments
Roche pledges to continuously review its study programs to determine if any adjustments are necessary for the purposes of ongoing research. This commitment to evaluation and adjustment underscores Roche’s dedication to exploring new treatment options and optimizing existing therapies for patients with NSCLC.-Fineline Info & Tech
